Forbes.com: Merck's FDA Delay, Pfizer's Problem
Forbes.com: Merck's FDA Delay, Pfizer's Problem: "Merck's FDA Delay, Pfizer's Problem
"NEW YORK - In a capstone to the withdrawal of Vioxx, the U.S. Food and Drug Administration has decided to delay the approval of successor drug Arcoxia until more safety data are available. But the news may not be as much a problem for Arcoxia's maker, Merck, as for rival Pfizer." [Forbes]
"NEW YORK - In a capstone to the withdrawal of Vioxx, the U.S. Food and Drug Administration has decided to delay the approval of successor drug Arcoxia until more safety data are available. But the news may not be as much a problem for Arcoxia's maker, Merck, as for rival Pfizer." [Forbes]
<< Home